97. 潰瘍性大腸炎
[臨床試験数:2,269,薬物数:1,331(DrugBank:241),標的遺伝子数:114,標的パスウェイ数:181

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04090411
(ClinicalTrials.gov)
December 19, 201912/9/2019A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Ulcerative ColitisA PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PF-06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITISModerate to Severe Ulcerative ColitisDrug: 50 mg;Drug: 450 mg;Drug: 150 mg;Other: 0 mgPfizerNULLRecruiting18 Years75 YearsAll240Phase 2United States;Australia;Belgium;Bulgaria;France;Hungary;India;Italy;Japan;Poland;Russian Federation;Slovakia;Spain;Thailand;Turkey;Ukraine;Canada;United Kingdom
2NCT01959282
(ClinicalTrials.gov)
November 15, 20137/10/2013A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative ColitisA Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects With Moderately to Severely Active Ulcerative ColitisColitis, UlcerativeDrug: Placebo;Drug: JNJ-54781532 25 mg once daily;Drug: JNJ-54781532 75 mg once daily;Drug: JNJ-54781532 150 mg once daily;Drug: JNJ-54781532 75 mg twice dailyJanssen Research & Development, LLCNULLCompleted18 YearsN/AAll219Phase 2United States;Australia;Belgium;Bulgaria;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Romania;Russian Federation;Ukraine
3JPRN-UMIN000008967
2009/01/0124/09/2012Efficacy of zinc-carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitis Ulcerative ColitisPolaprezinc group: Polaprezinc enema contained 150 mg of Polaprezinc suspension in tap water (total volume 100 mL) daily for one week

Placebo group: 100 mL tap water enema daily for one week
The Jikei University School of MedicineDivision of Gastroenterology and HepatologyNULLComplete: follow-up complete18years-oldNot applicableMale and Female30Not applicableJapan